Bio View : Investor Presentation- amendment

Investor Presentation

November 2022

Legal clarification/forward-looking information

The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein

This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of the Company' s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy, the any of the Company's securities in any jurisdiction.

The Company does not undertake to update or modify the information included in this presentation to reflect events or any changes involving data editing, processing, or segmentation other than as provided herein or any amendments that may be implemented after the preparation of this presentation. Please also note that the Company's plans and strategy as outlined in this presentation apply to the date of their publication and may be changed at the decision of the Board of Directors or the Company's management, as may happen from time to time. The evaluations in this presentation were provided by the Company's management and are not necessarily the only evaluations available.

This presentation includes forecasts, estimates, indexes, and other information relating to future events and/or matters whose occurrence is uncertain and are not under the Company's control. Such details are regarded as forward-looking information, as defined in the Securities Law, 5728-1968. Such events may not happen, in whole or in part, or may happen in a manner substantially different from any forecast. This forward-looking information is based on subjective assessments and assumptions by the Company's management and is derived from facts and data regarding the Company's current business activities. These subjective assessments and assumptions are inherently uncertain, as they involve risks that result from the Company's activities and are not controlled by the Company, any of which, or a combination thereof, may negatively affect the outcomes of such Company activities. Furthermore, should any forecasts and assessments turn out to be true or should any events or developments occur that have an impact on the general environment, market conditions, or external elements that affect Company activities, these shall be regarded as events that can neither be assessed beforehand nor be controlled by the Company. This presentation includes scientific, statistical, and other data published by third parties, the contents of which have not been reviewed by the Company.

Neither this presentation nor anything in it shall form a basis of any contract or commitment. This presentation is not intended to be relied upon as advice to invest for potential investors and does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate.

This presentation may contain information that has been or will be presented differently in reports published by the Company for the general public. Such information may include data characterized and/or edited and/or segmented differently in the reports published by the company for the general public.

2

Who we are

Company Established in 2000

Specializes in a variety of disciplines - R&D, manufacturing and marketing of cell imaging and analysis systems for cancer diagnostic testing

Global Distribution Agreements

•Abbott Molecular

•Sanmed Bio (China)

Company's systems regulatory approvals:

•FDA - USA

•NMPA - China

•CE IVDR - Europe

•Medical Device - Israel

• KFDA - Korea

Team of 25 employees

Global R&D and Service

Center in Rehovot, Israel

Over 650 systems installed around the world

Annual revenue from instrument sales and service contracts

of approximately 30 million NIS per year Profitable with a positive cash flow

Fully owned US subsidiary

engaging in marketing, sales, and rendering service to North American clients

BioView's instruments are sold to pathology, cytogenetics, and cytology laboratories

Business collaborations with industry leading liquid biopsy test manufacturers, which integrated the company instruments with their product offering

3

Our Mission:

To become a leading company developing, marketing, and selling liquid biopsy-basedmedical tests to improve the treatment and monitoring of cancer patients as well as minimize any discomfort and risks of existing tests

The company's expertise and market position

• Development and manufacturing of mechanical- optical automated systems for medical use
• Regulatory-approvedcell imaging systems
• Development of advanced image-processing algorithms
• Understanding of oncology laboratories workflows
• Proven experience in system characterization and implementation for innovative liquid biopsy testing
• A global reputation for expertise in automated imaging and detection of circulating cancer cells.

4

Areas of activity

1

2

Selling systems for clinical use to hospitals and laboratories

Selling systems to companies developing liquid biopsy tests

Advantages • Regulatory approvals in key markets

• Global distribution system
• Global reputation and customer base
• Market characterized by frequent system replacements

Challenges	• Recurring sales revenues generated through
	service contracts and upgrades

Advantages

Challenges

• BioView is at the technological forefront in the field of automated cell imaging and analysis
• A groundbreaking and required value proposition
• Potential for significant growth and profitability
• Strategic partnerships and potential for recurring revenues from clinical tests
• Relying on the successful deployment of liquid biopsy test developed by commercial partners
• Limited to the markets targeted by the commercial partner
• Uncertainty regarding the generation of constant revenues

5